New cancer pill ZX-8177 enters human testing for advanced tumors

NCT ID NCT07310134

Recruiting now Disease control Sponsor: Nanjing Zenshine Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental tablet called ZX-8177 in 80 Chinese patients with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and check for any signs that the drug can shrink tumors. It is a first step to see if the drug is worth testing in larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZX-8177 tablets
What this could lead to: If this trial succeeds, it could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 study with only 80 participants, so the drug may not prove safe or effective. It is also limited to Chinese patients, so results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Shanghai GoBroad Cancer Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.